A recap of the September Monthly Hamilton Health Check-up
What if the drug wasn’t in the needle, but was manufactured by your own cells? Hamilton’s Esphera SynBio is moving beyond traditional pharmaceuticals by pioneering a synthetic biology platform that reprograms your body’s cellular communication system to build, target, and deliver new cancer and infectious disease medicines in vivo.
Dr. Brian Lichty, co-founder of Esphera SynBio, detailed how the start-up is generating therapeutics within the body, while speaking at the Synapse Life Science Consortium’s Monthly Health Check-up session.
The Monthly Health Innovation Check-up is a virtual session that brings the life science community together to share updates, explore collaboration opportunities, and discuss the development and deployment of health innovations.
Harnessing Nature’s Nano-Vesicles
Esphera SynBio’s core technology is built upon exosomes—the tiny vesicles naturally used by all cells for communication throughout the body. The platform’s innovation is in manipulating this existing biology, acting “like a virus” to seamlessly insert its therapeutic function directly into the body’s processes.
The system delivers a transgene that programs a cell to produce modified exosomes. These therapeutic vesicles are engineered with three essential components:
- A Transmembrane Domain: Ensures the efficient loading of the payload into the exosome.
- A Targeting Domain: Directs the exosome to a specific cell type, such as an immune cell.
- A Cargo Enzyme: Delivers a potent therapeutic payload that generates the final medicine only in the target cell.
This in vivo manufacturing approach allows Esphera SynBio to bypass the complex, time-consuming, and expensive ex vivo exosome manufacturing challenges that have historically limited the field.
A Personalized Cancer Vaccine
Esphera SynBio’s lead clinical candidate is a potent, off-the-shelf cancer therapeutic designed to create a personalized cancer vaccine from the tumor itself. This approach targets solid tumors, which are high-volume exosome producers, to re-educate the immune system.
The result is a drug that is both personalized to the patient’s unique tumor biology and delivered as a scalable, off-the-shelf solution, addressing a major challenge in cancer immunotherapy. The company is planning IND-enabling studies in 2026, targeting a Phase 1 trial start in Q1 2027.
Esphera’s platform supports a robust pipeline focused on in vivo CAR T-cell generation and Enhanced mRNA vaccines. For CAR T therapy, the company uses targeted exosomes to deliver self-amplifying RNA, programming a patient’s T-cells inside the body and eliminating complex, costly ex vivo lab processing.
To fuel its clinical transition, the company is planning a multi-tranche Series A raise, with the first tranche targeted for Q1 2026.
Don’t miss the next virtual meeting. Sign-up here!
Interested in learning more about how Hamilton’s innovation ecosystem supports health start-ups? Connect with us to explore opportunities and resources to support your journey.